| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenocortical Carcinoma | 29 | 2023 | 172 | 9.520 |
Why?
|
| Adrenal Cortex Neoplasms | 30 | 2023 | 223 | 9.380 |
Why?
|
| Adrenal Gland Neoplasms | 21 | 2023 | 489 | 3.310 |
Why?
|
| Phenylurea Compounds | 10 | 2021 | 580 | 2.150 |
Why?
|
| Pheochromocytoma | 13 | 2023 | 281 | 2.080 |
Why?
|
| Thyroid Neoplasms | 21 | 2021 | 1866 | 1.880 |
Why?
|
| Cushing Syndrome | 6 | 2022 | 70 | 1.660 |
Why?
|
| Quinolines | 7 | 2021 | 383 | 1.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 3251 | 1.000 |
Why?
|
| Salvage Therapy | 5 | 2020 | 2054 | 0.910 |
Why?
|
| Adrenalectomy | 7 | 2022 | 188 | 0.910 |
Why?
|
| ACTH Syndrome, Ectopic | 4 | 2022 | 24 | 0.840 |
Why?
|
| Adrenal Glands | 3 | 2017 | 122 | 0.810 |
Why?
|
| Carcinoma | 6 | 2015 | 2578 | 0.800 |
Why?
|
| Paraganglioma | 7 | 2023 | 170 | 0.750 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1249 | 0.730 |
Why?
|
| Adrenocorticotropic Hormone | 6 | 2022 | 156 | 0.720 |
Why?
|
| Adrenocortical Adenoma | 4 | 2021 | 22 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-ret | 5 | 2017 | 370 | 0.680 |
Why?
|
| Niacinamide | 3 | 2014 | 421 | 0.610 |
Why?
|
| Antineoplastic Agents | 14 | 2021 | 14289 | 0.590 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 62 | 0.580 |
Why?
|
| Rare Diseases | 1 | 2020 | 351 | 0.580 |
Why?
|
| Adrenal Gland Diseases | 3 | 2020 | 72 | 0.550 |
Why?
|
| Mitotane | 4 | 2022 | 39 | 0.550 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 2 | 2017 | 53 | 0.530 |
Why?
|
| Fluorodeoxyglucose F18 | 6 | 2020 | 1226 | 0.520 |
Why?
|
| Endocrinology | 1 | 2017 | 139 | 0.520 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2015 | 142 | 0.510 |
Why?
|
| Humans | 91 | 2023 | 261506 | 0.510 |
Why?
|
| Hormones | 1 | 2015 | 266 | 0.500 |
Why?
|
| Neuroendocrine Tumors | 3 | 2022 | 634 | 0.490 |
Why?
|
| Young Adult | 27 | 2021 | 21445 | 0.480 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2021 | 4757 | 0.470 |
Why?
|
| Adult | 51 | 2023 | 77950 | 0.470 |
Why?
|
| Neoplasm Proteins | 2 | 2015 | 3230 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 5 | 2017 | 2330 | 0.470 |
Why?
|
| Ganglioneuroma | 1 | 2013 | 41 | 0.470 |
Why?
|
| Male | 57 | 2023 | 123000 | 0.470 |
Why?
|
| Middle Aged | 51 | 2023 | 86204 | 0.460 |
Why?
|
| Retrospective Studies | 36 | 2023 | 37905 | 0.460 |
Why?
|
| Renal Artery Obstruction | 1 | 2013 | 38 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 2 | 2011 | 895 | 0.430 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2022 | 7551 | 0.430 |
Why?
|
| Aged | 43 | 2021 | 70117 | 0.430 |
Why?
|
| Positron-Emission Tomography | 6 | 2020 | 2173 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2020 | 15862 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 419 | 0.420 |
Why?
|
| Iodine Radioisotopes | 5 | 2021 | 371 | 0.410 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2013 | 192 | 0.400 |
Why?
|
| Carcinoma, Medullary | 3 | 2015 | 248 | 0.380 |
Why?
|
| Plasmacytoma | 1 | 2011 | 111 | 0.370 |
Why?
|
| Female | 54 | 2022 | 141928 | 0.370 |
Why?
|
| Carcinoma, Neuroendocrine | 5 | 2017 | 716 | 0.370 |
Why?
|
| Bone Neoplasms | 6 | 2019 | 2576 | 0.360 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 29902 | 0.350 |
Why?
|
| Prognosis | 17 | 2023 | 21713 | 0.350 |
Why?
|
| Germ-Line Mutation | 4 | 2017 | 1046 | 0.350 |
Why?
|
| Myelolipoma | 2 | 2021 | 12 | 0.340 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2008 | 30 | 0.340 |
Why?
|
| Osteomalacia | 1 | 2008 | 36 | 0.340 |
Why?
|
| Neoplasm Metastasis | 9 | 2016 | 5112 | 0.330 |
Why?
|
| Fibroblast Growth Factors | 2 | 2017 | 257 | 0.330 |
Why?
|
| Hemangiopericytoma | 1 | 2008 | 56 | 0.330 |
Why?
|
| Medical Oncology | 1 | 2017 | 1423 | 0.320 |
Why?
|
| Immunotherapy | 2 | 2019 | 3341 | 0.320 |
Why?
|
| Hypoglycemia | 1 | 2010 | 213 | 0.320 |
Why?
|
| Hypercalcemia | 2 | 2007 | 137 | 0.310 |
Why?
|
| Endocrine System Diseases | 2 | 2020 | 83 | 0.300 |
Why?
|
| Hypothyroidism | 2 | 2021 | 204 | 0.300 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2008 | 315 | 0.300 |
Why?
|
| Diagnosis, Differential | 10 | 2020 | 4744 | 0.290 |
Why?
|
| Treatment Outcome | 19 | 2022 | 32848 | 0.280 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2017 | 45 | 0.280 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2011 | 406 | 0.280 |
Why?
|
| Anilides | 2 | 2020 | 268 | 0.270 |
Why?
|
| Hydrocortisone | 3 | 2023 | 388 | 0.270 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 2 | 2018 | 259 | 0.260 |
Why?
|
| Glycoproteins | 1 | 2008 | 747 | 0.260 |
Why?
|
| Registries | 3 | 2023 | 2170 | 0.240 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 52 | 0.240 |
Why?
|
| Kidney | 1 | 2013 | 2146 | 0.240 |
Why?
|
| Cervical Vertebrae | 1 | 2005 | 205 | 0.240 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2005 | 132 | 0.240 |
Why?
|
| Adrenal Insufficiency | 2 | 2021 | 49 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 5437 | 0.240 |
Why?
|
| Cysts | 1 | 2005 | 197 | 0.230 |
Why?
|
| Disease-Free Survival | 12 | 2017 | 10001 | 0.230 |
Why?
|
| Glucose | 1 | 2010 | 1248 | 0.230 |
Why?
|
| Signal Transduction | 3 | 2017 | 11965 | 0.230 |
Why?
|
| Case-Control Studies | 5 | 2021 | 6100 | 0.230 |
Why?
|
| Neoplasm Staging | 11 | 2023 | 13658 | 0.230 |
Why?
|
| Phosphoproteins | 1 | 2008 | 1152 | 0.220 |
Why?
|
| Thyroidectomy | 3 | 2017 | 486 | 0.220 |
Why?
|
| Cohort Studies | 8 | 2022 | 9244 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2008 | 2488 | 0.210 |
Why?
|
| Hypophysitis | 1 | 2021 | 10 | 0.200 |
Why?
|
| Tertiary Care Centers | 2 | 2013 | 403 | 0.200 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2022 | 475 | 0.200 |
Why?
|
| Platinum | 1 | 2021 | 138 | 0.190 |
Why?
|
| Pyridines | 2 | 2020 | 1244 | 0.190 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.190 |
Why?
|
| Adolescent | 18 | 2022 | 31252 | 0.190 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2020 | 8 | 0.190 |
Why?
|
| Adenoma | 2 | 2015 | 716 | 0.180 |
Why?
|
| Fatal Outcome | 4 | 2011 | 829 | 0.180 |
Why?
|
| Neoplasms | 4 | 2020 | 15193 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2021 | 684 | 0.180 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 486 | 0.180 |
Why?
|
| Spinal Neoplasms | 1 | 2005 | 631 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 14889 | 0.170 |
Why?
|
| Pituitary ACTH Hypersecretion | 2 | 2017 | 14 | 0.170 |
Why?
|
| Hyperglycemia | 1 | 2022 | 333 | 0.170 |
Why?
|
| Paraneoplastic Syndromes | 2 | 2011 | 82 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2022 | 899 | 0.170 |
Why?
|
| Cancer Care Facilities | 2 | 2013 | 884 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.160 |
Why?
|
| Urea | 1 | 2020 | 290 | 0.160 |
Why?
|
| Carcinoma, Papillary | 3 | 2014 | 584 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 2278 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 191 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 252 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 8873 | 0.160 |
Why?
|
| Survival Rate | 6 | 2020 | 12221 | 0.160 |
Why?
|
| Securin | 1 | 2017 | 11 | 0.160 |
Why?
|
| Internationality | 1 | 2019 | 208 | 0.160 |
Why?
|
| Disease Progression | 4 | 2020 | 6682 | 0.160 |
Why?
|
| Spinal Cord Compression | 2 | 2016 | 151 | 0.150 |
Why?
|
| Biomarkers, Tumor | 4 | 2017 | 10331 | 0.150 |
Why?
|
| Genomics | 2 | 2020 | 2738 | 0.150 |
Why?
|
| Survival Analysis | 7 | 2021 | 9180 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 3821 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2022 | 840 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2015 | 1987 | 0.140 |
Why?
|
| Neutrophils | 1 | 2021 | 835 | 0.140 |
Why?
|
| Oximes | 1 | 2017 | 175 | 0.140 |
Why?
|
| Risk Factors | 5 | 2020 | 17523 | 0.140 |
Why?
|
| Melanoma | 1 | 2013 | 5317 | 0.140 |
Why?
|
| Aluminum Silicates | 1 | 2015 | 15 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2017 | 314 | 0.130 |
Why?
|
| Antidiarrheals | 1 | 2015 | 37 | 0.130 |
Why?
|
| Exoribonucleases | 1 | 2015 | 42 | 0.130 |
Why?
|
| Receptors, Growth Factor | 1 | 2015 | 157 | 0.130 |
Why?
|
| Spinal Fractures | 1 | 2016 | 132 | 0.130 |
Why?
|
| Pyridones | 1 | 2017 | 348 | 0.130 |
Why?
|
| Histoplasmosis | 1 | 2015 | 74 | 0.130 |
Why?
|
| Carboplatin | 2 | 2015 | 823 | 0.130 |
Why?
|
| Pituitary Gland | 1 | 2015 | 150 | 0.130 |
Why?
|
| Prevalence | 1 | 2022 | 3260 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| 14-3-3 Proteins | 1 | 2015 | 143 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 8865 | 0.120 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2014 | 28 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 2316 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 543 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 144 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2015 | 298 | 0.120 |
Why?
|
| Everolimus | 1 | 2015 | 415 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3472 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 833 | 0.110 |
Why?
|
| Nervous System Neoplasms | 1 | 2013 | 36 | 0.110 |
Why?
|
| Incidence | 1 | 2023 | 5673 | 0.110 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 660 | 0.110 |
Why?
|
| Pituitary Neoplasms | 1 | 2015 | 203 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6207 | 0.110 |
Why?
|
| Candidiasis | 1 | 2015 | 262 | 0.110 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2013 | 115 | 0.110 |
Why?
|
| Atrophy | 1 | 2013 | 261 | 0.110 |
Why?
|
| Australia | 2 | 2023 | 225 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 5159 | 0.110 |
Why?
|
| Patient Selection | 1 | 2020 | 2055 | 0.110 |
Why?
|
| Imidazoles | 1 | 2017 | 999 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Bone Diseases | 1 | 2013 | 143 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 4849 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 3 | 2014 | 4975 | 0.100 |
Why?
|
| Lymphoma | 1 | 2020 | 1467 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2019 | 6869 | 0.100 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2011 | 31 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1910 | 0.100 |
Why?
|
| Diarrhea | 1 | 2015 | 686 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 11538 | 0.100 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2011 | 34 | 0.100 |
Why?
|
| Normetanephrine | 1 | 2010 | 4 | 0.100 |
Why?
|
| Cell Division | 1 | 2015 | 2489 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 4654 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2016 | 1756 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2013 | 485 | 0.100 |
Why?
|
| Paclitaxel | 2 | 2015 | 1996 | 0.100 |
Why?
|
| RNA Interference | 1 | 2015 | 1408 | 0.100 |
Why?
|
| Algorithms | 3 | 2021 | 3890 | 0.100 |
Why?
|
| Child | 10 | 2021 | 29154 | 0.100 |
Why?
|
| Phenylalanine | 1 | 2010 | 142 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 810 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 67 | 0.090 |
Why?
|
| Threonine | 1 | 2010 | 161 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2011 | 355 | 0.090 |
Why?
|
| Methionine | 1 | 2010 | 159 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 4988 | 0.090 |
Why?
|
| Alanine | 1 | 2010 | 240 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 2083 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 7702 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 551 | 0.090 |
Why?
|
| Metformin | 1 | 2013 | 378 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 502 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2015 | 992 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 2216 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 1162 | 0.090 |
Why?
|
| Infant | 2 | 2015 | 13310 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2012 | 2231 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 10035 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 4892 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2021 | 2588 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 305 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1503 | 0.080 |
Why?
|
| Pyrroles | 1 | 2012 | 576 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 1547 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 3719 | 0.080 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 214 | 0.080 |
Why?
|
| Heart Atria | 1 | 2010 | 352 | 0.080 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2011 | 323 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 2432 | 0.080 |
Why?
|
| Leg Ulcer | 1 | 2007 | 24 | 0.080 |
Why?
|
| Mice, Nude | 1 | 2015 | 4307 | 0.080 |
Why?
|
| Hypoxia | 1 | 2010 | 443 | 0.080 |
Why?
|
| Genome, Human | 1 | 2016 | 1869 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2020 | 557 | 0.070 |
Why?
|
| Contrast Media | 3 | 2020 | 1472 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 649 | 0.070 |
Why?
|
| Indoles | 1 | 2012 | 1009 | 0.070 |
Why?
|
| Transcriptome | 1 | 2015 | 1859 | 0.070 |
Why?
|
| Leg | 1 | 2007 | 226 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2021 | 16273 | 0.070 |
Why?
|
| Radiation Tolerance | 2 | 2021 | 629 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4298 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 3890 | 0.070 |
Why?
|
| HeLa Cells | 1 | 2008 | 1643 | 0.060 |
Why?
|
| United States | 5 | 2020 | 15433 | 0.060 |
Why?
|
| Comorbidity | 1 | 2011 | 2352 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5178 | 0.060 |
Why?
|
| Mice | 2 | 2015 | 34495 | 0.060 |
Why?
|
| Recurrence | 1 | 2012 | 4758 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2013 | 1225 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2013 | 1330 | 0.060 |
Why?
|
| Multimodal Imaging | 2 | 2020 | 550 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2006 | 462 | 0.060 |
Why?
|
| Animals | 4 | 2015 | 59536 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 7789 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 14551 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 2004 | 185 | 0.050 |
Why?
|
| Texas | 1 | 2013 | 6311 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 2422 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2017 | 1363 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 666 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 3981 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 690 | 0.050 |
Why?
|
| Adrenal Cortex Function Tests | 1 | 2020 | 8 | 0.050 |
Why?
|
| Androgens | 1 | 2023 | 511 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 163 | 0.050 |
Why?
|
| Adrenal Cortex | 1 | 2020 | 35 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 1283 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 661 | 0.050 |
Why?
|
| Germany | 1 | 2020 | 111 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5637 | 0.050 |
Why?
|
| Tablets | 1 | 2020 | 53 | 0.050 |
Why?
|
| Canada | 1 | 2020 | 429 | 0.040 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 60 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2020 | 12873 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 649 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 1301 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 319 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2020 | 272 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 750 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 4971 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 5539 | 0.040 |
Why?
|
| Steroid 21-Hydroxylase | 1 | 2017 | 8 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 160 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 397 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 109 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 437 | 0.040 |
Why?
|
| Angiopoietin-2 | 1 | 2017 | 38 | 0.040 |
Why?
|
| Mutation | 4 | 2017 | 15179 | 0.040 |
Why?
|
| Penetrance | 1 | 2017 | 126 | 0.040 |
Why?
|
| Observer Variation | 1 | 2018 | 671 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 343 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2017 | 153 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2403 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 4557 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 904 | 0.030 |
Why?
|
| Petrosal Sinus Sampling | 1 | 2015 | 3 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2018 | 355 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 690 | 0.030 |
Why?
|
| Organelle Biogenesis | 1 | 2015 | 32 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 395 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 4638 | 0.030 |
Why?
|
| Fatigue | 1 | 2021 | 1239 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2017 | 336 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2015 | 348 | 0.030 |
Why?
|
| Role | 1 | 2014 | 48 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 276 | 0.030 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2014 | 82 | 0.030 |
Why?
|
| Glutamine | 1 | 2015 | 299 | 0.030 |
Why?
|
| Succinate Dehydrogenase | 1 | 2013 | 43 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 604 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 1099 | 0.030 |
Why?
|
| Phenotype | 2 | 2020 | 6295 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2015 | 575 | 0.030 |
Why?
|
| Professional Practice | 1 | 2012 | 82 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 756 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 519 | 0.030 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 91 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 2013 | 159 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 980 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 2283 | 0.020 |
Why?
|
| Chromaffin System | 1 | 2010 | 7 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 827 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3203 | 0.020 |
Why?
|
| Time Factors | 2 | 2016 | 12926 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 15694 | 0.020 |
Why?
|
| Tanzania | 1 | 2010 | 68 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Radiography | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Catecholamines | 1 | 2010 | 101 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 177 | 0.020 |
Why?
|
| Altitude | 1 | 2010 | 39 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 1391 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 2450 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 1533 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1331 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2013 | 291 | 0.020 |
Why?
|
| Chronic Pain | 1 | 2013 | 238 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 586 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 3441 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 2803 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 1152 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2014 | 1529 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1546 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2017 | 2819 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 2669 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 1467 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8223 | 0.020 |
Why?
|
| Codon | 1 | 2004 | 241 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2004 | 331 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 7548 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1362 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 4532 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 1890 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 1382 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 4109 | 0.010 |
Why?
|